Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses new chemical compounds derived from cytisine and acetylcholine, specifically designed to modulate nicotinic acetylcholine receptors (nAChRs) in the nervous system. By functioning as agonists, partial agonists, or antagonists of specific nAChR subtypes (notably α4β2, α3β4, and α7), these molecules can influence mood-regulating pathways in the brain. The primary application is as novel therapeutic agents for the treatment of mood disorders such as major depressive disorder, bipolar disorder, dysthymia, postpartum depression, seasonal affective disorder, and schizoaffective disorder.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of major depressive disorder (MDD) in humans.
• As an adjunct therapy to classical antidepressants (e.g., tricyclics, MAO inhibitors, SSRIs) to enhance therapeutic response in mood disorders.
• Treatment of other mood disorders such as bipolar disorder, dysthymia, postpartum depression, seasonal affective disorder, and schizoaffective disorder.
• Development of medications targeting patients resistant to standard antidepressant therapies.
• Potential use in studying neurochemical pathways of mood disorders via selective receptor modulation.
• Pharmaceutical formulations for oral, parenteral, or alternative routes to treat mood disorders.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel mechanism of action for treating mood disorders by modulating specific nicotinic acetylcholine receptor subtypes, which is a different approach compared to most existing antidepressants.
• Compounds demonstrate high selectivity and binding affinity for target nAChRs, potentially improving efficacy and reducing side effects compared to less selective treatments.
• May produce antidepressant effects without the typical side-effects of current treatments and may not exacerbate underlying conditions such as anxiety or hyperactivity.
• Evidence of synergistic effect when co-administered with traditional antidepressants, possibly allowing dose reduction and improved patient outcomes.
• Potential for oral or injectable formulations, increasing flexibility for clinical use.
• Addresses unmet needs for patients with mood disorders that do not respond well to existing therapies.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to compounds which are derivatives of cytisine or acetylcholine which exhibit activity as agonists, partial agonists or antagonists of nicotinic acetylcholine receptors and may be used in modulating these receptors and in treating mood disorders in patients in need of therapy.